SubHero Banner

Genvoya® (elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide) – Expanded indication

September 26, 2017 – The FDA announced the approval of Gilead Sciences’ Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [TAF]) tablets, indicated as a complete regimen for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA < 50 copies/ mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Genvoya.

Download PDF